Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer.
Matulonis UA, Berlin S, Ivy P, Tyburski K, Krasner C, Zarwan C, Berkenblit A, Campos S, Horowitz N, Cannistra SA, Lee H, Lee J, Roche M, Hill M, Whalen C, Sullivan L, Tran C, Humphreys BD, Penson RT. Matulonis UA, et al. J Clin Oncol. 2009 Nov 20;27(33):5601-6. doi: 10.1200/JCO.2009.23.2777. Epub 2009 Oct 13. J Clin Oncol. 2009. PMID: 19826113 Free PMC article. Clinical Trial.
Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced mullerian tumors.
Penson RT, Dizon DS, Cannistra SA, Roche MR, Krasner CN, Berlin ST, Horowitz NS, Disilvestro PA, Matulonis UA, Lee H, King MA, Campos SM. Penson RT, et al. Among authors: berlin st. J Clin Oncol. 2010 Jan 1;28(1):154-9. doi: 10.1200/JCO.2009.22.7900. Epub 2009 Nov 16. J Clin Oncol. 2010. PMID: 19917843 Clinical Trial.
Phase II trial of GM-CSF in women with asymptomatic recurrent müllerian tumors.
Roche MR, Rudd PJ, Krasner CN, Matulonis UA, Berlin ST, Lee H, Silver M, Tran CD, Seiden MV, Penson RT. Roche MR, et al. Among authors: berlin st. Gynecol Oncol. 2010 Feb;116(2):168-72. doi: 10.1016/j.ygyno.2009.10.075. Epub 2009 Nov 18. Gynecol Oncol. 2010. PMID: 19922985 Clinical Trial.
Bevacizumab rechallenge after first line maintenance bevacizumab.
Konstantinopoulos PA, Berlin ST, Campos SM, Matulonis UA, Cannistra SA. Konstantinopoulos PA, et al. Among authors: berlin st. Gynecol Oncol. 2012 May;125(2):510-1. doi: 10.1016/j.ygyno.2012.02.013. Epub 2012 Feb 21. Gynecol Oncol. 2012. PMID: 22366591 Clinical Trial. No abstract available.
26 results